KRM-II-81 is a GABAA receptor potentiator, specifically an imidazodiazepine, being developed as a novel treatment for neurological and psychiatric disorders. It is being investigated for its potential in treating epilepsy, pain, and anxiety due to its ability to enhance the effects of GABA, a neurotransmitter that inhibits nerve activity. KRM-II-81 is showing promise in preclinical studies, particularly for pharmacoresistant epilepsy, and is also being explored for its potential in managing pain and anxiety. Its therapeutic use is listed as central nervous system (CNS) agents. The directory classifies it as a under development API with a synthetic source/manufacturing origin. Other names for this substance include Imidazobenzodiazepine derivative KRM-II-81. Its PubChem CID is 122582003.
Krm-II-81
| CAS No | 2014348-91-3 |
|---|---|
| Molecular Formula | C21H13N5O |
| Molecular Weight | 351.40 g/mol |
| Synonyms | 5-(8-ethynyl-6-pyridin-2-yl-4H-imidazo[1,5-a][1,4]benzodiazepin-3-yl)-1,3-oxazole |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
KRM-II-81 is a GABAA receptor potentiator, specifically an imidazodiazepine, being developed as a novel treatment for neurological and psychiatric disorders.
The listed CAS number is 2014348-91-3.
The listed molecular formula is C21H13N5O.
The listed molecular weight is 351.40 g/mol.
5-(8-ethynyl-6-pyridin-2-yl-4H-imidazo[1,5-a][1,4]benzodiazepin-3-yl)-1,3-oxazole.
The source lists Imidazobenzodiazepine derivative KRM-II-81.